*	OR T2 T3 T4
R1	Has_value Arg1:T1 Arg2:T2	
R2	Subsumes Arg1:T9 Arg2:T10	
*	OR T8 T9
R3	Has_qualifier Arg1:T8 Arg2:T7	
R4	Has_mood Arg1:T8 Arg2:T6	
*	OR T13 T14
R5	Has_qualifier Arg1:T12 Arg2:T13	
*	OR T16 T17
R6	AND Arg1:T12 Arg2:T16	
R7	AND Arg1:T8 Arg2:T12	
*	OR T20 T21
R9	multi Arg1:T23 Arg2:T22	
R8	Has_qualifier Arg1:T20 Arg2:T23	
R10	Has_mood Arg1:T20 Arg2:T19	
R11	Has_temporal Arg1:T25 Arg2:T27	
R12	Has_value Arg1:T25 Arg2:T26	
R13	Has_negation Arg1:T30 Arg2:T29	
R14	Has_negation Arg1:T32 Arg2:T31	
R15	Has_index Arg1:T38 Arg2:T41	
R16	Has_index Arg1:T39 Arg2:T40	
*	OR T38 T39
R17	Has_temporal Arg1:T37 Arg2:T38	
R18	Has_negation Arg1:T34 Arg2:T35	
*	OR T34 T36
R19	Has_multiplier Arg1:T34 Arg2:T33	
R20	AND Arg1:T28 Arg2:T30	
R21	Has_context Arg1:T28 Arg2:T32	
T1	Measurement 18 83	American Society of Anesthesiologists (ASA) Physical Status Class
T2	Value 84 85	1
T3	Value 87 88	2
T4	Value 93 94	3
T6	Mood 104 111	planned
T7	Qualifier 112 124	non-emergent
T8	Procedure 125 143	surgical procedure
T9	Condition 147 165	clinical situation
T10	Procedure 173 183	intubation
T12	Procedure 216 219	NMB
T13	Qualifier 199 207	moderate
T14	Qualifier 211 215	deep
T16	Drug 232 242	rocuronium
T17	Drug 246 256	vecuronium
T19	Mood 266 273	planned
T20	Procedure 274 292	surgical procedure
T21	Condition 296 314	clinical situation
T22	Procedure 332 377	objective neuromuscular monitoring techniques
T23	Qualifier 315 391	that would allow objective neuromuscular monitoring techniques to be applied
T25	Person 459 462	Age
T26	Value 463 485	between 2 to <17 years
T27	Temporal 486 496	at Visit 2
T28	Person 502 508	female
T29	Negation 536 539	not
T30	Condition 540 548	pregnant
T31	Negation 550 553	not
T32	Observation 554 567	breastfeeding
T33	Multiplier 573 585	at least one
T34	Condition 613 652	woman of childbearing potential (WOCBP)
T35	Negation 607 610	Not
T36	Condition 662 667	WOCBP
T37	Procedure 699 721	contraceptive guidance
T38	Temporal 722 749	during the treatment period
T39	Temporal 754 812	for at least 7 days after the last dose of study treatment
T40	Reference_point 780 812	the last dose of study treatment
T41	Reference_point 729 749	the treatment period
